Jingyi Fan

Dr. Jingyi Fan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
JFJingyi Fan
Jingyi Fan
HZHuaijun Zhou
Huaijun Zhou
Growth differentiation factor-10 (GDF10) with its methylation trait has recently been found to play a crucial regulatory and communication role in cancers. This investigation aims to identify GDF10 methylation site-associated genes that are closely associated with endometrial cancer (EC) patients’ survival based on normal and UCEC samples from the UCSC Xena database. Our study revealed for the first time that EC exhibited significantly higher levels of GDF10 promoter methylation in comparison with normal tissues. Multiple differentiated methylation sites, which have prognostic value due to their apparent survival differences, were found in the GDF10 promoter region. We performed weighted gene coexpression network analysis (WGCNA) on EC tissues and paraneoplastic tissues while using these differentially methylated sites as phenotypes for selecting the most correlated key modules and their internal genes. To obtain a gene set, the key module genes and differentially expressed genes (DEGs) of EC were intersected. The least absolute shrinkage and selection operator (LASSO) regression along with multivariate Cox regression were performed from the gene set and we screened out the key genes B4GALNT3, DNAJC22, and GREB1. Finally, a prognostic model was validated for effectiveness based on these genes. Additionally, Kaplan-Meier analysis and time-dependent receiver operating characteristics (ROC) were applied to assess and verify the model, and they showed good prognosis prediction. Moreover, the differences in risk scores were statistically significant with age, tumor stage, and grade. They may be related to the immune infiltration of tumors as well. In conclusion, based on the methylation-related genes associated with GDF10, we developed a prognosis model for EC patients. It might provide a fresh view for further research and treatment of EC.

25 November 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
XZXiaoyu Zhao
Xiaoyu Zhao
SLShuang Liang
Shuang Liang
NWNanxi Wang
Nanxi Wang
THTongtong Hong
Tongtong Hong
MSMuhammed Sambou
Muhammed Sambou
JDJun cheng Dai
Jun cheng Dai
Background: Previous studies have suggested associations between testosterone, genetic factors, and a series of complex diseases, but the associations with the lifespan phenotype, such as health span, remain unclear.Methods: In this prospective cohort study, we analyzed 145,481 men and 147,733 women aged 38–73 years old from UK Biobank (UKB) to investigate the sex-specific associations of total testosterone (TT), free testosterone (FT), or polygenic risk score (PRS) with health span termination (HST) risk. At baseline, serum testosterone levels were measured. HST was defined by eight events strongly associated with longevity. PRS, an efficient tool combining the effect of common genetic variants to discriminate genetic risk of complex phenotypes, was constructed by 12 single-nucleotide polymorphisms related to health span from UKB (P ≤ 5.0 × 10−8). We used multivariable Cox regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results: With a median follow-up time of 7.70 years, 26,748 (18.39%) men and 18,963 (12.84%) women had HST. TT was negatively associated with HST in men [HR per standard deviation (SD) increment of log-TT: 0.92, 95% CI: 0.88–0.97]. Inversely, both TT (HR per SD increment of log-TT: 1.05, 95% CI: 1.02–1.08) and FT (HR per SD increment of log-FT: 1.08, 95% CI: 1.05–1.11) presented an increased risk of HST in women. PRS was positively associated with HST risk (quintile 5 versus quintile 1, men, HR: 1.19, 95% CI: 1.15–1.24; women, HR: 1.21, 95% CI: 1.16–1.27). Moreover, men with high TT and low genetic risk showed the lowest HST risk (HR: 0.80, 95% CI: 0.73–0.88), whereas HST risk for women with both high TT and genetic risk increased obviously (HR: 1.32, 95% CI: 1.19–1.46). Similar joint effects were observed for FT in both genders.Conclusions: We observed sex-specific associations that testosterone was negatively associated with HST risk in men and positively associated with HST risk in women. Genetic factors increased the HST risk, suggesting that participants with both high genetic risk and abnormal testosterone levels (high level in women or low level in men) should be the target for early intervention. Although our findings highlight the associations between testosterone and health span, further mechanistic studies and prospective trials are warranted to explore the causation behind.

6 December 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
JYJuan Yang
Juan Yang
CTChan Tian
Chan Tian
MLMaojie Liu
Maojie Liu
HGHaiyan Guo
Haiyan Guo
FLFei Lin
Fei Lin
QZQun Zhang
Qun Zhang
Background/Objectives: Whether an increased genetic risk of steatotic liver disease (SLD) can be offset by maintaining a healthy weight remains unknown. We aimed to clarify the associations among the body mass index (BMI) and its change patterns with SLD and assess whether genetic susceptibility can modify these associations in Chinese people. Methods: A total of 10,091 and 6124 participants from the Health Omics Preventive Examination (HOPE) Program were enrolled in cross-sectional and follow-up analyses, respectively. BMI change patterns were defined according to the BMI at baseline and the last follow-up visit. Genetic risk was estimated using the polygenic risk score (PRS) derived from variants in PNPLA3, TM6SF2, MBOAT7, and GCKR. Data were analyzed using logistic regression models and Cox proportional-hazards models. Results: The analyses of the BMI and genetic risk simultaneously showed a dose–response association with the risk of SLD (p-trend < 0.001). Significant interactions between BMI and PRS were found for alanine aminotransferase (ALT) elevation (p = 0.007) and aspartate aminotransferase (AST) elevation (p < 0.001). Weight loss led to a 71%, 60%, and 67% lower risk of SLD, ALT elevation, and AST elevation, compared with stable overweight/obesity. A significant interaction between the genetic risk and BMI change patterns in ALT elevation was observed (p = 0.008). The absolute risk reductions associated with weight loss were greater for participants at a high genetic risk (26.60, 12.29, and 9.31 per 100 person years for SLD, ALT elevation, and AST elevation, respectively). Conclusions: Maintaining a healthy weight reduces the liver injury risk among all individuals, and the risk reduction is greater among the subset with a high genetic risk of SLD.

18 May 2023 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
RHRenfang Han
Renfang Han
JHJunxiang Huang
Junxiang Huang
NZNimei Zeng
Nimei Zeng
FXFangfei Xie
Fangfei Xie
YWYi Wang
Yi Wang
JFJingyi Fan
Jingyi Fan

13 June 2026 in BMC Endocrine Disorders
Verified
Journal Article
Open access
NZNimei Zeng
Nimei Zeng
TTTing Tian
Ting Tian
QZQuan Zhou
Quan Zhou
YLYuanli Li
Yuanli Li
RZRuixin Zhou
Ruixin Zhou
JFJingyi Fan
Jingyi Fan
We aimed to investigate and compare the performance of C-reactive protein-triglyceride glucose index (CTI) and remnant cholesterol inflammation index (RCII) in carotid atherosclerotic plaque (CAP) risk prediction. We conducted a case-control study (2,888 age- and sex-matched pairs) and a prospective cohort study of 4,418 participants without CAP (median follow-up: 767 days). Multivariable logistic and Cox regression were used to assess the associations of CTI and RCII with CAP. Receiver operating characteristic (ROC), net reclassification index (NRI) and integrated discrimination improvement (IDI) were calculated. In the case-control study, increased CTI (OR: 1.45, 95% CI: 1.16-1.80) and RCII (OR: 1.95, 95% CI: 1.66-2.29) were significantly associated with increased CAP risk. Similar associations with CAP were also observed in the cohort for CTI (HR: 1.79, 95% CI: 1.32-2.44) and RCII (HR: 2.02, 95% CI: 1.60-2.54). Moreover, adding CTI and RCII showed improvements in CAP risk prediction beyond the traditional model, with the area under the ROC curve of 0.681 for CTI, 0.704 for RCII and 0.702 for RCII+CTI (p < 0.05). RCII showed a superior ability to identify high-risk individuals with CAP compared with CTI, with a significant NRI of 0.119 (95% CI: 0.045-0.191) and IDI of 0.006 (95% CI: 0.002-0.011). Both CTI and RCII were significantly associated with increased risk of CAP, and RCII may be a superior biomarker to CTI in CAP risk prediction. Future large-scale cohort studies are needed to validate the predictive value of CTI and RCII for subclinical atherosclerosis. Not applicable.

19 May 2026 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
FXFangfei Xie
Fangfei Xie
YSYu’E Shen
Yu’E Shen
JZJing Zhao
Jing Zhao
XGXunzhi Geng
Xunzhi Geng
NZNimei Zeng
Nimei Zeng
JFJingyi Fan
Jingyi Fan
Metabolic dysfunction-associated fatty liver disease (MAFLD) poses a growing public health challenge, but traditional metabolic markers may not fully captu